DURHAM, N.C. – Chimerix, a biotechnology firm focused on developing treatments of smallpox and a virus related to organ transplants, has raised $23 million in venture funding.

The company plans to clinical trials with the funding, The News & Observer reported on Friday.

Investors included Canaan Partners and Alta Partners.